tetano
Editor, Senior Moderator
Eur J Pharmacol
. 2020 Jul 31;173455.
doi: 10.1016/j.ejphar.2020.173455. Online ahead of print.
Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting
Sourena Sharifkashani[SUP] 1 [/SUP], Melika Arab Bafrani[SUP] 2 [/SUP], Alireza Soltani Khaboushan[SUP] 1 [/SUP], Marzieh Pirzadeh[SUP] 3 [/SUP], Ali Kheirandish[SUP] 4 [/SUP], Hanie Yavarpour Bali[SUP] 3 [/SUP], Amirhossein Hessami[SUP] 5 [/SUP], Amene Saghazadeh[SUP] 6 [/SUP], Nima Rezaei[SUP] 7 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a beta coronavirus that uses the human angiotensin-converting enzyme 2 (ACE2) receptor as a point of entry. The present review discusses the origin and structure of the virus and its mechanism of cell entry followed by the therapeutic potentials of strategies directed towards SARS-CoV2-ACE2 binding, the renin-angiotensin system, and the kinin-kallikrein system. SARS-CoV2-ACE2 binding-directed approaches mainly consist of targeting receptor binding domain, ACE2 blockers, soluble ACE2, and host protease inhibitors. In conclusion, blocking or manipulating the SARS-CoV2-ACE2 binding interface perhaps offers the best tactic against the virus that should be treated as a fundamental subject of future research.
Keywords: ACE2; COVID-19; Origin; SARS-CoV2; Therapeutic; Transmission.
. 2020 Jul 31;173455.
doi: 10.1016/j.ejphar.2020.173455. Online ahead of print.
Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting
Sourena Sharifkashani[SUP] 1 [/SUP], Melika Arab Bafrani[SUP] 2 [/SUP], Alireza Soltani Khaboushan[SUP] 1 [/SUP], Marzieh Pirzadeh[SUP] 3 [/SUP], Ali Kheirandish[SUP] 4 [/SUP], Hanie Yavarpour Bali[SUP] 3 [/SUP], Amirhossein Hessami[SUP] 5 [/SUP], Amene Saghazadeh[SUP] 6 [/SUP], Nima Rezaei[SUP] 7 [/SUP]
Affiliations
- PMID: 32745604
- DOI: 10.1016/j.ejphar.2020.173455
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a beta coronavirus that uses the human angiotensin-converting enzyme 2 (ACE2) receptor as a point of entry. The present review discusses the origin and structure of the virus and its mechanism of cell entry followed by the therapeutic potentials of strategies directed towards SARS-CoV2-ACE2 binding, the renin-angiotensin system, and the kinin-kallikrein system. SARS-CoV2-ACE2 binding-directed approaches mainly consist of targeting receptor binding domain, ACE2 blockers, soluble ACE2, and host protease inhibitors. In conclusion, blocking or manipulating the SARS-CoV2-ACE2 binding interface perhaps offers the best tactic against the virus that should be treated as a fundamental subject of future research.
Keywords: ACE2; COVID-19; Origin; SARS-CoV2; Therapeutic; Transmission.